HIPRA will showcase its main R&D projects and new clinical data on its COVID-19 vaccine at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global, formerly known as ECCMID). The congress, which will bring together around 20,000 experts and specialists in the medical field, will take place from 27-30 April at Fira Gran Via in Barcelona, Spain.
HIPRA will participate as a sponsor with a booth (C-16) where the latest developments of the biotech pharmaceutical company will be presented, including the latest published study with interim results of HIPRA's new Omicron XBB-adjuvanted vaccine compared to an XBB-adjuvanted mRNA vaccine against SARS-CoV-2 variants XBB and JN.11.
The stand will also showcase innovations from GoodGut, the HIPRA group company dedicated to the development of gut microbiota-based solutions for the diagnosis of digestive diseases.
In the framework of the congress, HIPRA has organised a symposium under the title 'COVID-19 booster immunisation: key drivers for sustained protection'. It will take place on the first day of the congress, 27 April at 13:30 CET in Hall O, and will highlight the importance of scientific data in terms of strategic vaccination, bearing in mind that the duration and breadth of vaccine-induced immunity remains a field in progress if the needs of organisations to protect at-risk populations are to be met.
The HIPRA session, chaired by Chiara Iaria, ESCMID-appointed Chair and Arnas Civico Di Cristina Benfratelli (Italy) and José Antonio Navarro, Honorary Consultant to the Ministry of Health (Spain), will include four lectures by world-renowned experts.
Dan H. Barouch, from the Center for Virology and Vaccine Research at Harvard University (USA), will open the session with a presentation on the correlates of protection (CoP) of COVID-19 vaccines. He will be followed by Joan Puig-Barberà, from the vaccine research area of FISABIO in Valencia (Spain), explaining the importance of the RBD (receptor binding domain) to boost immunity against SARS-CoV-2 to cope with viral evolution. Sue Charlton from the Medical interventions group - UK Health Security Agency (UK) will also participate in the symposium with a presentation on vaccine protection against emerging variants of Omicron in the UK.
The session will end with a presentation by Ana Fernández-Sesma, ICAHN School of Medicine Mount Sinai (USA) on longitudinal cohort studies of vaccination against SARS-CoV-2, influenza and dengue, based on the immune phenotype of participants. By participating in this congress, HIPRA reaffirms its commitment to research and development of solutions that contribute to global health
1. Lopez MJ, Narejos S, Castro A, et al. Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial. MedRxiv 2024. DOI: 10.1101/2024.04.19.24306064